NEW YORK, Sept. 11 – Quark Biotech said Tuesday that Mitsubishi-Tokyo Pharmaceuticals of Japan has made an equity investment in the company of an undisclosed amount.

Quark and Mitsubishi-Tokyo, a wholly owned subsidiary of Mitsubishi Chemical Corporation, are currently collaborating to develop drug targets for neurodegenerative diseases as well as other disease areas.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.